monitoringandvascularaccessof,1550
postoperativecare,fast-trackingandtransitionto,1550–1551
preoperativeassessmentof,1547–1548,1548t
preparationandpreproceduralsedationof,1548
Aneurysms
aorticroot,1080–1081,1081t
ofsinusesofValsalva,959–960,960f
clinicalmanifestationsof,960
investigationsof,960–961,961f
managementof,961–962
ofveinofGalen,929–931
clinicalmanifestationof,929
diagnosisof,929–930,929f–930f
managementof,930–931,930f–931f
Angiocardiography,incommonarterialtrunk,750–751,751f
Angiogenesis,65–66
Angiography,indiagnosticcatheterization,242–243
Angiotensin-convertingenzymeinhibition,for“well”Fontan,1338–1339
Angiotensinconvertingenzymeinhibitors(ACEIs),1437–1438
forcancertherapy-relatedcardiotoxicity,1171
forchronicheartfailure,1199–1200
fordilatedcardiomyopathy,1158
forhypertension,1139,1140t
forinterstagemanagement,1309
AngiotensinII,incontrolofcirculation,1359
Angiotensinreceptorblockers,fordilatedcardiomyopathy,1158
Angiotensinreceptor/neprilysininhibitors,forchronicheartfailure,1201
Annulus,775,945
Anomalousaorticorigin
ofcoronaryartery,873–875,873f
cardiopulmonaryexercisestresstestingof,874
clinicalpresentationof,873
computedtomographicangiographyandmagneticresonanceimagingof,874
diagnostictestingof,873–874
echocardiographyof,873–874,874f
outcomesfor,875
pathophysiologyof,873
surgicalinterventionfor,874–875
surgicaltechniquesfor,875
ofpulmonaryartery,952–956,955f
clinicalfeaturesof,956
managementof,956
Anomalouspulmonaryveins,476–477
indiagnosticcatheterization,249
Anomalouspulmonaryvenousreturn,318t
Anomalousrightcoronaryartery,frompulmonarytrunk,872–873
Anomaloussystemicvenousanomalies,457–474
withanomalousdrainage,464–468
cavalveinsandhepaticveins,474
connectionbutnormaldrainage,461–464
diagnosisof,471–474
cardiacmagneticresonanceimaging,472
catheterangiography,474
computedtomographicangiography,472
salinecontrastechocardiography,472,473f
managementof,474
portosystemicshunts,474
umbilicalandvitellineveins,471
Anorexianervosa,cardiacinvolvementin,1113
Antegradecerebralperfusion,selective,incardiopulmonarybypass,231
Anteriorheartfield,50
Anteroposteriorcamera,243
Anthracyclinederivatives,forcancertherapy-relatedcardiotoxicity,1171
Anthropometry,1496
Antiarrhythmics,1437
Antibody-mediatedfetalheartdisease,142–144
Antibradycardiapacing,365
Anticoagulants,1435–1436
Anticoagulation
incardiopulmonarybypass,230
fordilatedcardiomyopathy,1159
forFontanfailure,1345–1346
ininterventionaltechniques,255
oral,forpulmonaryhypertension,1389
pregnancyand,1033–1034
for“well”Fontan,1337–1338
Antifibrinolytics,1289–1290
Antihypertensives,1437–1438
Antiinflammatoryagents,formyocarditis,1177
Antimicrobialtherapy,forinfectiveendocarditis,1051–1061,1052t–1053t
Antithrombotictherapy,forinfectiveendocarditis,1057
Aorta,1355
abdominal,echocardiographicquantificationandidentificationofpatternsofflowin,303,303f
anatomyof,26,26f
ascending
anomalousoriginofapulmonaryarteryfrom,909
channelsfrom,totheleftorrightpulmonaryartery,908–909,908f–909f
echocardiographicquantificationandidentificationofpatternsofflowin,305,305f
coarctationof,Coarctationofaorta
descending,echocardiographicquantificationandidentificationofpatternsofflowin,305,305f
indiagnosticcatheterization,251
double-barreledordoublelumen,883,887f,903–906,907f
medialabnormalitiesof,systemicarterialdysfunctionand,1373
Aortic“annulus,”,819,821,821f
Aorticarch
anomaliesof,877
causingtrachealandesophagealcompression,managementof,893–898
classificationof,877–878
clinicalfindingsof,886–888
diagnosticinvestigationsof,888–891,888f–891f
incidence,genetics,andassociationwith,883–886